Adicet Bio Inc (ACET)

Overview News Price History Option Chain Discussions Forecast

Adicet Bio Inc stock is currently priced at $2.10, with a 24-hour trading volume of 1.13M. It has seen a +5.00% increased in the last 24 hours and a -4.11% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $2.00 pivot point. If it approaches the $2.13 resistance level, significant changes may occur.

Adicet Bio Inc Stock (ACET) Financials Data

Adicet Bio Inc (ACET) Revenue 2024

ACET reported a revenue (TTM) of $38.70 million for the quarter ending March 31, 2022, a +224.62% rise year-over-year.

Adicet Bio Inc (ACET) Net Income 2024

ACET net income (TTM) was -$143.04 million for the quarter ending September 30, 2023, a -156.68% decrease year-over-year.

Adicet Bio Inc (ACET) Cash Flow 2024

ACET recorded a free cash flow (TTM) of -$99.89 million for the quarter ending September 30, 2023, a -89.39% decrease year-over-year.

Adicet Bio Inc (ACET) Earnings per Share 2024

ACET earnings per share (TTM) was -$3.35 for the quarter ending September 30, 2023, a -129.45% decline year-over-year.

Adicet Bio Inc Stock (ACET) Latest News

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors or T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Its products pipeline includes ADI-001, which is in Phase 1 clinical study to treat non-Hodgkin's lymphoma; and ADI-002 that is in Phase 1 clinical study for the treatment of hepatocellular carcinoma and other solid tumors. The company is based in Menlo Park, California.

Downgrade	Guggenheim: Buy → Neutral	Jun-27-23
Downgrade	JMP Securities: Mkt Outperform → Mkt Perform	Jun-27-23
Downgrade	JP Morgan: Overweight → Neutral	Jun-01-23
Initiated	JP Morgan: Overweight	Sep-21-22
Initiated	SMBC Nikko: Outperform	Mar-31-22
Initiated	Truist: Buy	Mar-08-22
Initiated	Jefferies: Buy	Mar-04-22
Initiated	BTIG Research: Buy	May-18-21
Initiated	H.C. Wainwright: Buy	Apr-23-21
Initiated	Canaccord Genuity: Buy	Apr-14-21
Initiated	Guggenheim: Buy	Apr-08-21
Initiated	B. Riley Securities: Buy	Nov-04-20
Initiated	JMP Securities: Mkt Outperform	Oct-27-20
Initiated	Wedbush: Outperform	Oct-16-20